Dr. Zujewski Discusses Breast Cancer Drug Development

Jo Anne Zujewski, MD
Published Online: Thursday, October 3, 2013
Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute (NCI), discusses the development of drugs to treat patients with breast cancer.

In the past, when breast cancer was considered a more homogenous disease, if a drug demonstrated a response rate of less that 10%, it was not thought to be worth developing. With the advent of actionable mutations and targeted therapeutics, there is now a need to determine which patients are exceptional responders. If an agent demonstrates a 1-10% response rate, it is worthwhile to develop for those patients who would see great benefit, Zujewski says.

The NCI is now focusing on exceptional responders and molecular identification, which requires nationwide laboratory testing to identify mutations and beneficial drugs that can be administered.

Online CME Activities
Free CME from PER
Advances in Next-Generation Sequencing in Precision Oncology: Solid Tumors
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast Cancer
Newer Options on the Horizon for Non-Small Cell Lung Cancer
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
More Reading
$auto_registration$